Tech Company Financing Transactions
Adagene Funding Round
On 1/9/2020, Adagene announced $69 million in Series D funding from General Atlantic and private investors.
Transaction Overview
Company Name
Announced On
1/9/2020
Transaction Type
Venture Equity
Amount
$69,000,000
Round
Series D
Investors
General Atlantic (Lead Investor) (Lefei Sun)
Proceeds Purpose
This financial commitment enables us to continue developing our lead clinical programs, ADG106 and ADG116, while extending the frontiers of our novel technology.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
315 Montgomery St.
San Francisco, CA 94104
USA
San Francisco, CA 94104
USA
Phone
Undisclosed
Website
Email Address
Overview
Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Luo
Chief Financial Officer
Raymond Tam
Chief Scientific Officer
Felix Du
Vice President
Yan Li
VP - Bus. Development
Alexander Goergen
VP - Operations
Kristine She
Browse more venture capital transactions:
Prev: 1/9/2020: Alitheon venture capital transaction
Next: 1/9/2020: Vecna Robotics venture capital transaction
Share this article
News on VC Transactions
We record every notable VC transaction. All VC database entries reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs